Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Cash from Investing Activities: 2021-2025

Historic Cash from Investing Activities for ProQR Therapeutics N.V (PRQR) over the last 3 years, with Jun 2025 value amounting to -$114,328.

  • ProQR Therapeutics N.V's Cash from Investing Activities rose 60.24% to -$114,328 in Q2 2025 from the same period last year, while for Jun 2025 it was -$19.9 million, marking a year-over-year decrease of 36.87%. This contributed to the annual value of -$4.4 million for FY2024, which is 194.05% down from last year.
  • ProQR Therapeutics N.V's Cash from Investing Activities amounted to -$114,328 in Q2 2025, which was up 51.48% from -$235,622 recorded in Q1 2025.
  • Over the past 5 years, ProQR Therapeutics N.V's Cash from Investing Activities peaked at $5.4 million during Q4 2023, and registered a low of -$19.3 million during Q1 2024.
  • Over the past 3 years, ProQR Therapeutics N.V's median Cash from Investing Activities value was -$261,576 (recorded in 2024), while the average stood at -$1.9 million.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Cash from Investing Activities soared by 27,652.30% in 2023, and later slumped by 20,065.28% in 2024.
  • ProQR Therapeutics N.V's Cash from Investing Activities (Quarterly) stood at -$189,899 in 2021, then spiked by 110.21% to $19,385 in 2022, then spiked by 27,652.30% to $5.4 million in 2023, then grew by 10.19% to -$287,529 in 2024, then skyrocketed by 60.24% to -$114,328 in 2025.
  • Its Cash from Investing Activities was -$114,328 in Q2 2025, compared to -$235,622 in Q1 2025 and -$287,529 in Q2 2024.